Product nameAnti-PDE4D antibody
See all PDE4D primary antibodies
DescriptionRabbit polyclonal to PDE4D
Tested applicationsSuitable for: ICC/IF, WBmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human PDE4D aa 750 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in Human lung tissue lysate as well as the following whole cell lysates: DU145; A549.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab87329 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 5 µg/ml.|
|WB||1/250. Detects a band of approximately 81 kDa (predicted molecular weight: 91 kDa).|
FunctionHydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Tissue specificityWidespread; most abundant in skeletal muscle. Isoform 6 is detected in brain. Isoform 8 is detected in brain, placenta, lung and kidney. Isoform 7 is detected in heart and skeletal muscle.
PathwayPurine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.
Involvement in diseaseNote=Genetic variations in PDE4D might be associated with susceptibility to stroke. PubMed:17006457 states that association with stroke has to be considered with caution.
Sequence similaritiesBelongs to the cyclic nucleotide phosphodiesterase family. PDE4 subfamily.
modificationsIsoform 3 and isoform 7 are activated by phosphorylation (in vitro), but not isoform 6. Isoform N3 and isoform 12 are phosphorylated on Ser-49, Ser-51, Ser-55 and Ser-59.
Cellular localizationCytoplasm. Membrane. Cytoplasm > cytoskeleton. Cytoplasm > cytoskeleton > centrosome. Found in the soluble fraction, associated with membranes, and associated with the cytoskeleton and the centrosome.
- Information by UniProt
- cAMP specific 3',5' cyclic phosphodiesterase 4D antibody
- DKFZp686M11213 antibody
- 5''-cyclic phosphodiesterase 4D antibody
All lanes : Anti-PDE4D antibody (ab87329) at 1 µg/ml
Lane 1 : DU 145 (Human prostate carcinoma cell line) Whole Cell Lysate
Lane 2 : Lung (Human) Tissue Lysate
Lane 3 : A549 (Human lung adenocarcinoma epithelial cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 91 kDa
Observed band size: 81 kDa why is the actual band size different from the predicted?
Additional bands at: 28 kDa, 70 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 20 minutes
The predicted molecular weight of Human cAMP-specific 3',5'-cyclic phosphodiesterase 4D is 71 kDa(SwissProt), however we expect to observe a banding pattern at 81 kDa. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.
ICC/IF image of ab87329 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab87329, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) HeLa cells at 5µg/ml.
ab87329 has not yet been referenced specifically in any publications.